World

Jalen Hurts Diagnosed with Blood Clots, Out for Season

Philadelphia Eagles quarterback Jalen Hurts is expected to miss the remainder of the season due to blood clots in his lungs, according to the team's announcement.

20 October 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Jalen Hurts Diagnosed with Blood Clots, Out for Season — Photo: All-Pro Reels · Wikimedia Commons · CC BY-SA 2.0

The Philadelphia Eagles announced that quarterback Jalen Hurts will miss the remainder of the season following a diagnosis that revealed blood clots in his lungs. The team indicated that the blood clots had originated from deep vein thrombosis in his leg, confirmed after further testing.

Hurts's condition is reported to be stable, with no significant functional limitations, according to the team's update. He is currently undergoing treatment involving blood thinners and is advised against contact sports during this time.

Despite Hurts experiencing a serious health issue, the Eagles are optimistic about his recovery. The team expects him to make a full recovery, although he is set to be sidelined for the entire season.

Reports indicate that Hurts had played despite not having slept for 36 hours before the diagnosis, which may have contributed to his condition. The decision to place him on the injured reserve list was made to ensure his safety while undergoing treatment.

Replacements for Hurts on the field have been discussed, with Tanner McKee stepping in as the starter for the Eagles. The decision marks a significant change for the team's lineup as they adjust to his absence.

Experts note that similar cases in professional athletes often require extensive recovery time. It can take more than six months for players to return to their previous levels of performance after such conditions, raising questions about the impact on Hurts's career moving forward.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.